COVID-19  Vaccine Immunogenicity and Safety in ImmunoDeficient Patients

Our project’s aim is to learn more about the effectiveness, safety, and immune response in individuals with low or compromised immune systems who have been vaccinated with the Pfizer-BioNTech or Moderna mRNA or Astrazeneca COVID-19 vaccines. Interested in joining our study? We are currently recruiting the following participants from across Canada:

  • All ages considered eligible by Health Canada to receive the COVID-19 vaccinations who are either healthy or have primary immunodeficiency (inborn error of immunity) or have been on immunotherapy such as rituximab, ocrelizumab for medical conditions AND:
    • Have not been vaccinated but plan to be vaccinated against COVID-19, or
    • Have received their primary series (2 doses for healthy participants or 3 doses for immunocompromised participants) of the COVID-19 Pfizer/BioNTech, Moderna mRNA, or AstraZeneca vaccination, or
    • Were fully vaccinated including first booster (Dose 3 for healthy participants or Dose 4 for immunocompromised participants) against COVID-19 less than 24 weeks ago.

Enroll Now

Our Study